- Home
- PLRX vs LEU Comparison
PLRX vs LEU Comparison
Compare PLRX & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- LEU
- Stock Information
- Founded
- PLRX 2015
- LEU 1998
- Country
- PLRX United States
- LEU United States
- Employees
- PLRX N/A
- LEU N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- PLRX Health Care
- LEU Industrials
- Exchange
- PLRX Nasdaq
- LEU Nasdaq
- Market Cap
- PLRX 682.2M
- LEU 1.2B
- IPO Year
- PLRX 2020
- LEU 1998
- Fundamental
- Price
- PLRX $10.87
- LEU $90.60
- Analyst Decision
- PLRX Strong Buy
- LEU Buy
- Analyst Count
- PLRX 7
- LEU 2
- Target Price
- PLRX $40.50
- LEU $92.00
- AVG Volume (30 Days)
- PLRX 509.0K
- LEU 567.4K
- Earning Date
- PLRX 02-26-2025
- LEU 02-06-2025
- Dividend Yield
- PLRX N/A
- LEU N/A
- EPS Growth
- PLRX N/A
- LEU 50.42
- EPS
- PLRX N/A
- LEU 4.70
- Revenue
- PLRX N/A
- LEU $394,000,000.00
- Revenue This Year
- PLRX N/A
- LEU $25.25
- Revenue Next Year
- PLRX N/A
- LEU $5.68
- P/E Ratio
- PLRX N/A
- LEU $19.30
- Revenue Growth
- PLRX N/A
- LEU 14.94
- 52 Week Low
- PLRX $10.22
- LEU $33.51
- 52 Week High
- PLRX $18.92
- LEU $118.36
- Technical
- Relative Strength Index (RSI)
- PLRX 35.54
- LEU 66.57
- Support Level
- PLRX $10.94
- LEU $68.10
- Resistance Level
- PLRX $12.70
- LEU $74.66
- Average True Range (ATR)
- PLRX 0.72
- LEU 5.56
- MACD
- PLRX -0.19
- LEU 2.10
- Stochastic Oscillator
- PLRX 4.78
- LEU 86.95
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.